Journal of bronchology & interventional pulmonology · 2026
Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Detection of PET-CT Negative Contralateral Hilar Lymph Node Metastasis in the Staging of Non-small cell Lung Cancer.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tharwani Arsal, Shaller Brian, Aravena Carlos, Rathunde Lucas, Sarda Yash, Cicenia Joseph, Sethi Sonali, Ribeiro Neto Manuel L, Choi Humberto, Gillespie Colin, Gildea Thomas, Lam Louis, Mehta Atul, Machuzak Michael, Mazzone Peter, Wang Yifan, Almeida Francisco A
Аннотация
BACKGROUND: The detection rate of contralateral hilar involvement in NSCLC during EBUS-TBNA staging is not well established.
METHODS: We conducted a retrospective observational single-center study of all EBUS-TBNA staging examinations performed from 2016 through 2020 to determine the incidence of PET and CT negative N3 hilar metastasis by EBUS-TBNA in patients with radiographic T1-T4, N0-N3, M0 NSCLC.
RESULTS: A total of 516 patients underwent EBUS-TBNA sampling of contralateral hilar lymph nodes. Metastatic non-small cell lung cancer was detected in one or more contralateral hilar lymph node stations in 5 patients (0.97%). Four of these patients had radiographic N2 or N3 disease on PET imaging. Patients with mediastinal N2/N3 disease by PET scan were at higher risk of having occult contralateral hilar disease as compared with mediastinal N0/N1 by PET (P=0.017). In individuals radiographically staged as mediastinal N3 by CT scan, 14 (95% CI: 3-78) patients would need to undergo EBUS-TBNA sampling of a CT negative contralateral hilar lymph node to identify malignant involvement of the latter. In cases radiographically staged as mediastinal N3 by PET scan, 25 (95% CI: 6-141) patients would need to undergo EBUS-TBNA sampling of a PET-negative contralateral hilar lymph node to identify malignancy involvement in this location.
CONCLUSION: In patients with NSCLC undergoing EBUS staging for radiographic N0/N1 disease by PET, it is reasonable to not sample the contralateral hilar lymph node stations. In radiographic N2/N3 disease by PET or CT, sampling the contralateral hilar lymph node stations appears to be justified.
METHODS: We conducted a retrospective observational single-center study of all EBUS-TBNA staging examinations performed from 2016 through 2020 to determine the incidence of PET and CT negative N3 hilar metastasis by EBUS-TBNA in patients with radiographic T1-T4, N0-N3, M0 NSCLC.
RESULTS: A total of 516 patients underwent EBUS-TBNA sampling of contralateral hilar lymph nodes. Metastatic non-small cell lung cancer was detected in one or more contralateral hilar lymph node stations in 5 patients (0.97%). Four of these patients had radiographic N2 or N3 disease on PET imaging. Patients with mediastinal N2/N3 disease by PET scan were at higher risk of having occult contralateral hilar disease as compared with mediastinal N0/N1 by PET (P=0.017). In individuals radiographically staged as mediastinal N3 by CT scan, 14 (95% CI: 3-78) patients would need to undergo EBUS-TBNA sampling of a CT negative contralateral hilar lymph node to identify malignant involvement of the latter. In cases radiographically staged as mediastinal N3 by PET scan, 25 (95% CI: 6-141) patients would need to undergo EBUS-TBNA sampling of a PET-negative contralateral hilar lymph node to identify malignancy involvement in this location.
CONCLUSION: In patients with NSCLC undergoing EBUS staging for radiographic N0/N1 disease by PET, it is reasonable to not sample the contralateral hilar lymph node stations. In radiographic N2/N3 disease by PET or CT, sampling the contralateral hilar lymph node stations appears to be justified.